| Overview |
| bs-6008R |
| GADD45GIP1 Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GADD45GIP1 |
| 121-222/222 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 90480 |
| Nucleus |
| CKBBP2; CKII beta associating protein; CKII beta binding protein 2; CKII beta-associating protein; CR6 interacting factor 1; CR6-interacting factor 1; CR1; G45IP_HUMAN; Gadd45gip1; growth arrest and DNA damage inducible, gamma interacting protein 1; Growth arrest and DNA damage-inducible proteins-interacting protein 1; p53 responsive gene 6; p53 responsive gene 6 protein; p53-responsive gene 6 protein; Papillomavirus L2 interacting nuclear protein 1; Papillomavirus L2-interacting nuclear protein 1; PLINP 1; PLINP-1; PLINP1; PRG6. |
| Acts as a negative regulator of G1 to S cell cycle phase progression by inhibiting cyclin-dependent kinases. Inhibitory effects are additive with GADD45 proteins but occurs also in the absence of GADD45 proteins. Acts as a repressor of the orphan nuclear receptor NR4A1 by inhibiting AB domain-mediated transcriptional activity. May be involved in the hormone-mediated regulation of NR4A1 transcriptional activity. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz